Ainos (AIMD) Competitors $0.62 -0.01 (-1.68%) As of 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends AIMD vs. RNXT, AKTX, IXHL, CVM, LSTA, CGTX, INKT, KALA, MRNS, and UBXShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include RenovoRx (RNXT), Akari Therapeutics (AKTX), Incannex Healthcare (IXHL), CEL-SCI (CVM), Lisata Therapeutics (LSTA), Cognition Therapeutics (CGTX), MiNK Therapeutics (INKT), KALA BIO (KALA), Marinus Pharmaceuticals (MRNS), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical products" industry. Ainos vs. RenovoRx Akari Therapeutics Incannex Healthcare CEL-SCI Lisata Therapeutics Cognition Therapeutics MiNK Therapeutics KALA BIO Marinus Pharmaceuticals Unity Biotechnology RenovoRx (NASDAQ:RNXT) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Which has stronger valuation and earnings, RNXT or AIMD? RenovoRx has higher earnings, but lower revenue than Ainos. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovoRxN/AN/A-$10.23M-$0.57-2.70Ainos$120K72.21-$13.77MN/AN/A Does the MarketBeat Community believe in RNXT or AIMD? RenovoRx received 9 more outperform votes than Ainos when rated by MarketBeat users. CompanyUnderperformOutperformRenovoRxOutperform Votes947.37% Underperform Votes1052.63% AinosN/AN/A Does the media favor RNXT or AIMD? In the previous week, Ainos had 2 more articles in the media than RenovoRx. MarketBeat recorded 2 mentions for Ainos and 0 mentions for RenovoRx. Ainos' average media sentiment score of 0.37 beat RenovoRx's score of 0.00 indicating that Ainos is being referred to more favorably in the news media. Company Overall Sentiment RenovoRx Neutral Ainos Neutral Is RNXT or AIMD more profitable? Ainos' return on equity of -75.16% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets RenovoRxN/A -205.96% -110.01% Ainos N/A -75.16%-50.22% Do institutionals & insiders have more ownership in RNXT or AIMD? 3.1% of RenovoRx shares are owned by institutional investors. 7.1% of RenovoRx shares are owned by company insiders. Comparatively, 10.4% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, RNXT or AIMD? RenovoRx has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Ainos has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Do analysts recommend RNXT or AIMD? RenovoRx currently has a consensus price target of $6.50, indicating a potential upside of 322.08%. Given RenovoRx's stronger consensus rating and higher probable upside, equities analysts clearly believe RenovoRx is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAinos beats RenovoRx on 7 of the 13 factors compared between the two stocks. Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.67M$6.58B$5.40B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A10.0188.8317.53Price / Sales72.21335.371,284.8780.52Price / CashN/A22.6336.6032.90Price / Book0.125.084.964.69Net Income-$13.77M$154.90M$117.89M$224.57M7 Day Performance-12.14%2.59%2.74%3.33%1 Month Performance36.33%1.52%3.63%5.33%1 Year Performance-47.44%5.49%27.26%22.97% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos1.3173 of 5 stars$0.62-1.7%N/A-46.5%$8.67M$120,000.000.0040News CoverageRNXTRenovoRx1.3016 of 5 stars$1.35+1.5%$6.50+381.5%+38.9%$32.40MN/A-2.376AKTXAkari TherapeuticsN/A$1.21-0.4%N/A-53.7%$32.03MN/A0.009Analyst ForecastGap DownIXHLIncannex HealthcareN/A$1.80-2.7%N/A-52.2%$31.76M$86,000.00-1.293CVMCEL-SCIN/A$0.41-2.4%N/A-83.4%$31.46MN/A-0.7243LSTALisata Therapeutics2.6275 of 5 stars$3.67-1.6%$15.00+308.7%+25.8%$30.81MN/A-1.4630News CoveragePositive NewsCGTXCognition Therapeutics2.5501 of 5 stars$0.74-2.7%$8.30+1,021.5%-70.4%$30.75MN/A-0.7620INKTMiNK Therapeutics2.4692 of 5 stars$0.77+5.9%$6.50+739.9%+0.0%$30.67MN/A-1.9830KALAKALA BIO4.0318 of 5 stars$6.55-3.8%$15.00+129.0%-2.3%$30.20M$3.89M-0.5330MRNSMarinus Pharmaceuticals4.6261 of 5 stars$0.54+0.8%$4.79+784.4%-94.4%$29.88M$31.47M-0.22110Analyst ForecastUBXUnity Biotechnology4.4593 of 5 stars$1.72-3.9%$7.33+326.4%+3.6%$28.98M$240,000.00-1.3160 Related Companies and Tools Related Companies RNXT Competitors AKTX Competitors IXHL Competitors CVM Competitors LSTA Competitors CGTX Competitors INKT Competitors KALA Competitors MRNS Competitors UBX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AIMD) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
